Download Image
    
Share
  
Post
rhu-pGSN for COVID-19
1 study with 61 patients
Hospital Icon Control
Hospital Icon rhu-pGSN Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 rhu-pGSN studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -3% Mortality -3% RCTs -3% Late -3% Favorsrhu-pGSN Favorscontrol
Recombinant human plasma gelsolin (rhu-pGSN) is a biologic therapy that functions as a host-directed anti-inflammatory and immunomodulatory agent.
Jul 25
2022
 DiNubile et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac357 Adjunctive Recombinant Human Plasma Gelsolin for Severe Coronavirus Disease 2019 Pneumonia
3% higher mortality (p=1), 48% lower ventilation (p=0.47), and 29% higher progression (p=0.73). RCT 61 hospitalized patients with COVID-19 pneumonia showing no significant difference in survival without major organ support with recombinant human plasma gelsolin (rhu-pGSN). This double-blind, placebo-controlled trial evaluated rhu-pG..